Dian Diagnostics Group Co.,Ltd. (300244.SZ)
CNY 13.79
(0.95%)
CNY 13.79
(0.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.02 Billion CNY | -30.55% |
| 2022 | 11.55 Billion CNY | 42.32% |
| 2021 | 8.11 Billion CNY | 27.44% |
| 2020 | 6.36 Billion CNY | 13.51% |
| 2019 | 5.61 Billion CNY | -5.88% |
| 2018 | 5.96 Billion CNY | 34.2% |
| 2017 | 4.44 Billion CNY | 40.08% |
| 2016 | 3.17 Billion CNY | 157.15% |
| 2015 | 1.23 Billion CNY | 203.14% |
| 2014 | 406.86 Million CNY | 83.54% |
| 2013 | 221.67 Million CNY | 23.96% |
| 2012 | 178.82 Million CNY | 44.61% |
| 2011 | 123.65 Million CNY | 66.35% |
| 2010 | 74.33 Million CNY | 8.73% |
| 2009 | 68.36 Million CNY | -17.59% |
| 2008 | 82.96 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.7 Billion CNY | -3.04% |
| 2024 Q3 | 7.59 Billion CNY | -1.38% |
| 2024 Q1 | 7.94 Billion CNY | -0.98% |
| 2023 FY | 8.02 Billion CNY | -30.55% |
| 2023 Q4 | 8.02 Billion CNY | -3.97% |
| 2023 Q1 | 10.97 Billion CNY | -5.02% |
| 2023 Q3 | 8.35 Billion CNY | -10.49% |
| 2023 Q2 | 9.33 Billion CNY | -14.94% |
| 2022 Q3 | 10.73 Billion CNY | -3.72% |
| 2022 Q1 | 9.11 Billion CNY | 12.32% |
| 2022 FY | 11.55 Billion CNY | 42.32% |
| 2022 Q4 | 11.55 Billion CNY | 7.6% |
| 2022 Q2 | 11.15 Billion CNY | 22.31% |
| 2021 Q3 | 7.68 Billion CNY | 9.31% |
| 2021 Q1 | 6.73 Billion CNY | 5.65% |
| 2021 FY | 8.11 Billion CNY | 27.44% |
| 2021 Q4 | 8.11 Billion CNY | 5.59% |
| 2021 Q2 | 7.03 Billion CNY | 4.51% |
| 2020 Q2 | 6.77 Billion CNY | 20.41% |
| 2020 Q1 | 5.62 Billion CNY | 0.28% |
| 2020 FY | 6.36 Billion CNY | 13.51% |
| 2020 Q3 | 6.67 Billion CNY | -1.56% |
| 2020 Q4 | 6.36 Billion CNY | -4.5% |
| 2019 Q1 | 5.87 Billion CNY | -1.46% |
| 2019 FY | 5.61 Billion CNY | -5.88% |
| 2019 Q2 | 6.03 Billion CNY | 2.76% |
| 2019 Q3 | 5.69 Billion CNY | -5.69% |
| 2019 Q4 | 5.61 Billion CNY | -1.44% |
| 2018 Q3 | 5.56 Billion CNY | -0.38% |
| 2018 Q2 | 5.58 Billion CNY | 29.26% |
| 2018 Q1 | 4.32 Billion CNY | -2.76% |
| 2018 FY | 5.96 Billion CNY | 34.2% |
| 2018 Q4 | 5.96 Billion CNY | 7.19% |
| 2017 FY | 4.44 Billion CNY | 40.08% |
| 2017 Q2 | 3.57 Billion CNY | 10.05% |
| 2017 Q3 | 3.94 Billion CNY | 10.28% |
| 2017 Q1 | 3.25 Billion CNY | 2.52% |
| 2017 Q4 | 4.44 Billion CNY | 12.59% |
| 2016 Q3 | 2.75 Billion CNY | 56.13% |
| 2016 Q1 | 990.1 Million CNY | -19.72% |
| 2016 FY | 3.17 Billion CNY | 157.15% |
| 2016 Q4 | 3.17 Billion CNY | 14.97% |
| 2016 Q2 | 1.76 Billion CNY | 78.45% |
| 2015 Q2 | 754.01 Million CNY | 31.7% |
| 2015 Q1 | 572.54 Million CNY | 40.72% |
| 2015 Q3 | 1.1 Billion CNY | 46.26% |
| 2015 Q4 | 1.23 Billion CNY | 11.84% |
| 2015 FY | 1.23 Billion CNY | 203.14% |
| 2014 FY | 406.86 Million CNY | 83.54% |
| 2014 Q4 | 406.86 Million CNY | 61.71% |
| 2014 Q1 | 166.56 Million CNY | -24.86% |
| 2014 Q3 | 251.6 Million CNY | 10.57% |
| 2014 Q2 | 227.55 Million CNY | 36.61% |
| 2013 Q4 | 221.67 Million CNY | -6.05% |
| 2013 Q2 | 232.28 Million CNY | 22.04% |
| 2013 Q1 | 190.32 Million CNY | 6.43% |
| 2013 FY | 221.67 Million CNY | 23.96% |
| 2013 Q3 | 235.96 Million CNY | 1.59% |
| 2012 Q2 | 179.16 Million CNY | 51.76% |
| 2012 Q1 | 118.06 Million CNY | -4.53% |
| 2012 Q3 | 162.41 Million CNY | -9.35% |
| 2012 FY | 178.82 Million CNY | 44.61% |
| 2012 Q4 | 178.82 Million CNY | 10.11% |
| 2011 Q3 | 97 Million CNY | -6.17% |
| 2011 Q4 | 123.65 Million CNY | 27.47% |
| 2011 Q2 | 103.38 Million CNY | 41.81% |
| 2011 Q1 | 72.9 Million CNY | -1.92% |
| 2011 FY | 123.65 Million CNY | 66.35% |
| 2010 Q4 | 74.33 Million CNY | 0.0% |
| 2010 FY | 74.33 Million CNY | 8.73% |
| 2009 FY | 68.36 Million CNY | -17.59% |
| 2008 FY | 82.96 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | -53.444% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | -535.526% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | -451.795% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -938.604% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | -432.184% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | -593.479% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -1204.249% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | -122.339% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -3530.142% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -697.083% |